Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Monopar Therapeutics Inc (MNPR).
Monopar Therapeutics Inc. has announced that Professor Rodney Hicks, a globally renowned radiopharmaceutical expert, will spearhead the Phase 1 dosimetry clinical trial of MNPR-101-Zr in advanced cancer patients. This move marks a significant step in the company’s efforts to advance its cancer treatment research.
See more data about MNPR stock on TipRanks’ Stock Analysis page.